Efficacy of nitazoxanide, tizoxanide and tizoxanide/albendazole sulphoxide combination against Taenia crassiceps cysts

Objectives: Neurocysticercosis is a common parasitic disease in the CNS in humans caused by the metacestode Taenia solium, with high incidence in developing countries. Albendazole is the drug of choice. However, a wide interindividual variability in the response has been reported. In order to evalua...

Full description

Saved in:
Bibliographic Details
Published inJournal of antimicrobial chemotherapy Vol. 59; no. 2; pp. 212 - 218
Main Authors Palomares-Alonso, Francisca, Piliado, Juan Carlos, Palencia, Guadalupe, Ortiz-Plata, Alma, Jung-Cook, Helgi
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.02.2007
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objectives: Neurocysticercosis is a common parasitic disease in the CNS in humans caused by the metacestode Taenia solium, with high incidence in developing countries. Albendazole is the drug of choice. However, a wide interindividual variability in the response has been reported. In order to evaluate alternative treatment options, the in vitro efficacy of nitazoxanide, its main metabolite tizoxanide as well as the tizoxanide and albendazole sulphoxide combination was tested against Taenia crassiceps cysts. Methods: T. crassiceps cysts were incubated in culture medium containing different concentrations of nitazoxanide, tizoxanide and albendazole sulphoxide (0.037–0.42 μg/mL). The effect of the tizoxanide and albendazole sulphoxide combination was evaluated in a fixed-concentration ratio (1:1). Isobolographic analyses were used to define the kind of interaction between drugs. Morphological and ultrastructural alterations over the parasite tissue were observed by light and transmission electron microscopy. Results: Nitazoxanide and tizoxanide exhibited cestocidal activity which was time–concentration-dependent. The EC50 values were 0.15, 0.12 and 0.080 μg/mL for nitazoxanide, tizoxanide and albendazole sulphoxide, respectively. No statistical differences between EC50 values were found, indicating that nitazoxanide and tizoxanide are equally potent as albendazole sulphoxide. The effect of the tizoxanide and albendazole sulphoxide combination was faster than that observed with each drug alone. Isobolographic analysis showed that the effect of the combination was additive. Nitazoxanide and tizoxanide had an effect on the germinal layer, where lipid droplets were found. Nitazoxanide and tizoxanide produced less damage than albendazole sulphoxide on the germinal layer. After the tizoxanide and albendazole sulphoxide combination, a high accumulation of lipid droplets within the germinal layer of the parasite was found. Conclusions: Our results suggest that nitazoxanide in combination with albendazole could be useful for treatment of cysticercosis infections. Additional in vivo studies are required to confirm this hypothesis.
AbstractList Neurocysticercosis is a common parasitic disease in the CNS in humans caused by the metacestode Taenia solium, with high incidence in developing countries. Albendazole is the drug of choice. However, a wide interindividual variability in the response has been reported. In order to evaluate alternative treatment options, the in vitro efficacy of nitazoxanide, its main metabolite tizoxanide as well as the tizoxanide and albendazole sulphoxide combination was tested against Taenia crassiceps cysts. T. crassiceps cysts were incubated in culture medium containing different concentrations of nitazoxanide, tizoxanide and albendazole sulphoxide (0.037-0.42 microg/mL). The effect of the tizoxanide and albendazole sulphoxide combination was evaluated in a fixed-concentration ratio (1:1). Isobolographic analyses were used to define the kind of interaction between drugs. Morphological and ultrastructural alterations over the parasite tissue were observed by light and transmission electron microscopy. Nitazoxanide and tizoxanide exhibited cestocidal activity which was time-concentration-dependent. The EC(50) values were 0.15, 0.12 and 0.080 microg/mL for nitazoxanide, tizoxanide and albendazole sulphoxide, respectively. No statistical differences between EC(50) values were found, indicating that nitazoxanide and tizoxanide are equally potent as albendazole sulphoxide. The effect of the tizoxanide and albendazole sulphoxide combination was faster than that observed with each drug alone. Isobolographic analysis showed that the effect of the combination was additive. Nitazoxanide and tizoxanide had an effect on the germinal layer, where lipid droplets were found. Nitazoxanide and tizoxanide produced less damage than albendazole sulphoxide on the germinal layer. After the tizoxanide and albendazole sulphoxide combination, a high accumulation of lipid droplets within the germinal layer of the parasite was found. Our results suggest that nitazoxanide in combination with albendazole could be useful for treatment of cysticercosis infections. Additional in vivo studies are required to confirm this hypothesis.
Objectives: Neurocysticercosis is a common parasitic disease in the CNS in humans caused by the metacestode Taenia solium, with high incidence in developing countries. Albendazole is the drug of choice. However, a wide interindividual variability in the response has been reported. In order to evaluate alternative treatment options, the in vitro efficacy of nitazoxanide, its main metabolite tizoxanide as well as the tizoxanide and albendazole sulphoxide combination was tested against Taenia crassiceps cysts. Methods: T. crassiceps cysts were incubated in culture medium containing different concentrations of nitazoxanide, tizoxanide and albendazole sulphoxide (0.037-0.42 μg/mL). The effect of the tizoxanide and albendazole sulphoxide combination was evaluated in a fixed-concentration ratio (1:1). Isobolographic analyses were used to define the kind of interaction between drugs. Morphological and ultrastructural alterations over the parasite tissue were observed by light and transmission electron microscopy. Results: Nitazoxanide and tizoxanide exhibited cestocidal activity which was time-concentration-dependent. The EC50 values were 0.15, 0.12 and 0.080 μg/mL for nitazoxanide, tizoxanide and albendazole sulphoxide, respectively. No statistical differences between EC50 values were found, indicating that nitazoxanide and tizoxanide are equally potent as albendazole sulphoxide. The effect of the tizoxanide and albendazole sulphoxide combination was faster than that observed with each drug alone. Isobolographic analysis showed that the effect of the combination was additive. Nitazoxanide and tizoxanide had an effect on the germinal layer, where lipid droplets were found. Nitazoxanide and tizoxanide produced less damage than albendazole sulphoxide on the germinal layer. After the tizoxanide and albendazole sulphoxide combination, a high accumulation of lipid droplets within the germinal layer of the parasite was found. Conclusions: Our results suggest that nitazoxanide in combination with albendazole could be useful for treatment of cysticercosis infections. Additional in vivo studies are required to confirm this hypothesis.
Objectives: Neurocysticercosis is a common parasitic disease in the CNS in humans caused by the metacestode Taenia solium, with high incidence in developing countries. Albendazole is the drug of choice. However, a wide interindividual variability in the response has been reported. In order to evaluate alternative treatment options, the in vitro efficacy of nitazoxanide, its main metabolite tizoxanide as well as the tizoxanide and albendazole sulphoxide combination was tested against Taenia crassiceps cysts. Methods: T. crassiceps cysts were incubated in culture medium containing different concentrations of nitazoxanide, tizoxanide and albendazole sulphoxide (0.037-0.42 microg/mL). The effect of the tizoxanide and albendazole sulphoxide combination was evaluated in a fixed-concentration ratio (1:1). Isobolographic analyses were used to define the kind of interaction between drugs. Morphological and ultrastructural alterations over the parasite tissue were observed by light and transmission electron microscopy. Results: Nitazoxanide and tizoxanide exhibited cestocidal activity which was time-concentration-dependent. The EC50 values were 0.15, 0.12 and 0.080 microg/mL for nitazoxanide, tizoxanide and albendazole sulphoxide, respectively. No statistical differences between EC50 values were found, indicating that nitazoxanide and tizoxanide are equally potent as albendazole sulphoxide. The effect of the tizoxanide and albendazole sulphoxide combination was faster than that observed with each drug alone. Isobolographic analysis showed that the effect of the combination was additive. Nitazoxanide and tizoxanide had an effect on the germinal layer, where lipid droplets were found. Nitazoxanide and tizoxanide produced less damage than albendazole sulphoxide on the germinal layer. After the tizoxanide and albendazole sulphoxide combination, a high accumulation of lipid droplets within the germinal layer of the parasite was found. Conclusions: Our results suggest that nitazoxanide in combination with albendazole could be useful for treatment of cysticercosis infections. Additional in vivo studies are required to confirm this hypothesis. [PUBLICATION ABSTRACT]
Objectives: Neurocysticercosis is a common parasitic disease in the CNS in humans caused by the metacestode Taenia solium, with high incidence in developing countries. Albendazole is the drug of choice. However, a wide interindividual variability in the response has been reported. In order to evaluate alternative treatment options, the in vitro efficacy of nitazoxanide, its main metabolite tizoxanide as well as the tizoxanide and albendazole sulphoxide combination was tested against Taenia crassiceps cysts. Methods: T. crassiceps cysts were incubated in culture medium containing different concentrations of nitazoxanide, tizoxanide and albendazole sulphoxide (0.037–0.42 μg/mL). The effect of the tizoxanide and albendazole sulphoxide combination was evaluated in a fixed-concentration ratio (1:1). Isobolographic analyses were used to define the kind of interaction between drugs. Morphological and ultrastructural alterations over the parasite tissue were observed by light and transmission electron microscopy. Results: Nitazoxanide and tizoxanide exhibited cestocidal activity which was time–concentration-dependent. The EC50 values were 0.15, 0.12 and 0.080 μg/mL for nitazoxanide, tizoxanide and albendazole sulphoxide, respectively. No statistical differences between EC50 values were found, indicating that nitazoxanide and tizoxanide are equally potent as albendazole sulphoxide. The effect of the tizoxanide and albendazole sulphoxide combination was faster than that observed with each drug alone. Isobolographic analysis showed that the effect of the combination was additive. Nitazoxanide and tizoxanide had an effect on the germinal layer, where lipid droplets were found. Nitazoxanide and tizoxanide produced less damage than albendazole sulphoxide on the germinal layer. After the tizoxanide and albendazole sulphoxide combination, a high accumulation of lipid droplets within the germinal layer of the parasite was found. Conclusions: Our results suggest that nitazoxanide in combination with albendazole could be useful for treatment of cysticercosis infections. Additional in vivo studies are required to confirm this hypothesis.
Author Palencia, Guadalupe
Palomares-Alonso, Francisca
Jung-Cook, Helgi
Piliado, Juan Carlos
Ortiz-Plata, Alma
Author_xml – sequence: 1
  givenname: Francisca
  surname: Palomares-Alonso
  fullname: Palomares-Alonso, Francisca
  organization: Laboratorio de Neuropsicofarmacología, Instituto Nacional de Neurología y Neurocirugía 14269 México D.F., México
– sequence: 2
  givenname: Juan Carlos
  surname: Piliado
  fullname: Piliado, Juan Carlos
  organization: Laboratorio de Neuropsicofarmacología, Instituto Nacional de Neurología y Neurocirugía 14269 México D.F., México
– sequence: 3
  givenname: Guadalupe
  surname: Palencia
  fullname: Palencia, Guadalupe
  organization: Laboratorio de Neuroinmunología Instituto Nacional de Neurología y Neurocirugía 14269, México D.F., México
– sequence: 4
  givenname: Alma
  surname: Ortiz-Plata
  fullname: Ortiz-Plata, Alma
  organization: Laboratorio de Neuropatología Instituto Nacional de Neurología y Neurocirugía 14269, México D.F., México
– sequence: 5
  givenname: Helgi
  surname: Jung-Cook
  fullname: Jung-Cook, Helgi
  email: helgi@servidor.unam.mx, *Correspondence address. Instituto Nacional de Neurología y Neurocirugía, Insurgentes Sur 3877, Col. La Fama, Tlalpan 14269, México City, México. Tel/Fax: +52-54-24-08-08; helgi@servidor.unam.mx
  organization: Laboratorio de Neuropsicofarmacología, Instituto Nacional de Neurología y Neurocirugía 14269 México D.F., México
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18539053$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/17114175$$D View this record in MEDLINE/PubMed
BookMark eNp90N9rFDEQB_AgFXutvvgHSBB8EddLNr82j1L7QygIUrH0JcwmWc11L9kmu3LnX--WOz2ffJoZ-MwMfE_QUUzRI_SSkveUaLZcgV26-55L9gQtKJekqommR2hBGBGV4oIdo5NSVoQQKWTzDB1TRSmnSizQz_OuCxbsFqcOxzDCr7SBGJx_h8fwp8cQ3T_jEvrWRzfT3uMy9cOPtHlUNq3bEGEMKWL4DiGWEd-AjwGwzVBKsH4o2G7LWJ6jpx30xb_Y11P09eL85uyquv58-ensw3VlOZdjxblTtPZEQ60Epx3oVrnaWmE5iEZTC9Lq2jXe26ZtpfO69ayhteocF_MqO0Wvd3eHnB4mX0azSlOO80tTUyV1wwSZ0dsdsjmVkn1nhhzWkLeGEvOYsJkTNruEZ_xqf3Fq194d6D7SGbzZAygW-i5DtKEcXCOYJoIdXJqG_z-sdi6U0W_-Ssj3RiqmhLm6vTPfbj_e1ZfNhfnCfgOh-KT9
CODEN JACHDX
CitedBy_id crossref_primary_10_1016_j_actatropica_2016_03_022
crossref_primary_10_1016_j_actatropica_2021_106027
crossref_primary_10_1016_j_jsps_2016_09_005
crossref_primary_10_1517_14656560902722463
crossref_primary_10_1016_j_exppara_2011_11_001
crossref_primary_10_1016_j_exppara_2019_107792
crossref_primary_10_1017_S0031182020000505
crossref_primary_10_1039_D2RA03314C
crossref_primary_10_1007_s00436_014_3846_4
crossref_primary_10_1155_2019_8578936
crossref_primary_10_1016_j_exppara_2012_03_017
crossref_primary_10_1007_s11686_022_00526_4
crossref_primary_10_1016_j_heliyon_2023_e19472
crossref_primary_10_1016_j_actatropica_2018_12_017
crossref_primary_10_1016_j_exppara_2010_06_025
crossref_primary_10_4155_tde_2020_0017
crossref_primary_10_1017_S003118200999117X
crossref_primary_10_1128_AAC_01465_12
crossref_primary_10_1016_j_meegid_2014_02_005
crossref_primary_10_1007_s00436_013_3589_7
crossref_primary_10_2165_00003495_200767130_00015
crossref_primary_10_1007_s00436_017_5614_8
crossref_primary_10_1016_j_actatropica_2019_105238
crossref_primary_10_1128_AAC_01022_12
crossref_primary_10_1186_1471_2377_10_16
crossref_primary_10_1016_j_exppara_2016_10_012
ContentType Journal Article
Copyright The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org 2006
2007 INIST-CNRS
The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Copyright_xml – notice: The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org 2006
– notice: 2007 INIST-CNRS
– notice: The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7QO
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
NAPCQ
P64
DOI 10.1093/jac/dkl463
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Toxicology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Nursing & Allied Health Premium
Biotechnology Research Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
DatabaseTitleList MEDLINE

Virology and AIDS Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1460-2091
EndPage 218
ExternalDocumentID 1317810171
10_1093_jac_dkl463
17114175
18539053
10.1093/jac/dkl463
ark_67375_HXZ_WXDZ2G8F_R
Genre Journal Article
Feature
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
0R~
18M
1TH
29J
2WC
3O-
4.4
482
48X
53G
5GY
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAJKP
AAJQQ
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWTL
ABEJV
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABPTD
ABQLI
ABQNK
ABQTQ
ABWST
ABXVV
ABZBJ
ACCCW
ACGFO
ACGFS
ACIWK
ACPRK
ACUFI
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AFXEN
AGINJ
AGKEF
AGQXC
AGSYK
AGUTN
AHMBA
AHXPO
AIAGR
AIJHB
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APWMN
ASPBG
ATGXG
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BSCLL
BTRTY
BVRKM
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
ECGQY
EE~
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HH5
HVGLF
HW0
HZ~
IOX
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBS
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RHF
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZO
TCURE
TEORI
TJX
TMA
TR2
UCJ
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZKX
~91
6.Y
AAPGJ
AASNB
AAWDT
ABSAR
ABSMQ
ACFRR
ACMRT
ACPQN
ACUTJ
ACZBC
AEKPW
AFSHK
AFYAG
AGKRT
AGMDO
AI.
APJGH
AQDSO
AQKUS
ATTQO
AVNTJ
BZKNY
EIHJH
MBLQV
O~Y
QBD
RNI
RZF
VH1
Y6R
ZGI
ZXP
~A~
AABJS
AABMN
AAESY
AAIYJ
AANRK
ABPTK
ACIMA
ADEIU
ADORX
ADQLU
AIKOY
AIMBJ
ALXQX
ASMCH
AWCFO
AZQFJ
BGYMP
BYORX
CASEJ
DPORF
DPPUQ
IQODW
OBFPC
AEHUL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7QO
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
NAPCQ
P64
ID FETCH-LOGICAL-c446t-44d712e09a27541fa9b7d2cc5c4a5891ca6c92d8eec8bb6de9be38127fd45d713
ISSN 0305-7453
IngestDate Thu Oct 10 22:13:35 EDT 2024
Thu Sep 12 17:59:54 EDT 2024
Tue Oct 15 23:46:49 EDT 2024
Sun Oct 22 16:07:54 EDT 2023
Wed Aug 28 03:24:32 EDT 2024
Wed Oct 30 09:38:29 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords antiparasitics
drug interactions
activity
metacestodes ultrastructure
Anthelmintic
Treatment efficiency
Plathelmintha
in vitro activity
Cestoda
In vitro
Biological activity
Albendazole
Nitazoxanide
Benzimidazole derivatives
Ultrastructure
Cyst
Helmintha
Parasiticide
Drug interaction
Benign neoplasm
Taenia crassiceps
Invertebrata
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c446t-44d712e09a27541fa9b7d2cc5c4a5891ca6c92d8eec8bb6de9be38127fd45d713
Notes istex:90944161DC5A178F6A646A691ACFBC4E241D961B
ark:/67375/HXZ-WXDZ2G8F-R
OpenAccessLink https://academic.oup.com/jac/article-pdf/59/2/212/2149872/dkl463.pdf
PMID 17114175
PQID 217698350
PQPubID 32192
PageCount 7
ParticipantIDs proquest_journals_217698350
crossref_primary_10_1093_jac_dkl463
pubmed_primary_17114175
pascalfrancis_primary_18539053
oup_primary_10_1093_jac_dkl463
istex_primary_ark_67375_HXZ_WXDZ2G8F_R
PublicationCentury 2000
PublicationDate 2007-02-01
PublicationDateYYYYMMDD 2007-02-01
PublicationDate_xml – month: 02
  year: 2007
  text: 2007-02-01
  day: 01
PublicationDecade 2000
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: England
PublicationTitle Journal of antimicrobial chemotherapy
PublicationTitleAlternate J Antimicrob Chemother
PublicationYear 2007
Publisher Oxford University Press
Oxford Publishing Limited (England)
Publisher_xml – name: Oxford University Press
– name: Oxford Publishing Limited (England)
SSID ssj0006568
Score 2.0654168
Snippet Objectives: Neurocysticercosis is a common parasitic disease in the CNS in humans caused by the metacestode Taenia solium, with high incidence in developing...
Neurocysticercosis is a common parasitic disease in the CNS in humans caused by the metacestode Taenia solium, with high incidence in developing countries....
SourceID proquest
crossref
pubmed
pascalfrancis
oup
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 212
SubjectTerms Albendazole - analogs & derivatives
Albendazole - pharmacology
Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Anticestodal Agents - pharmacology
antiparasitics
Bacteria
Biological and medical sciences
Chemotherapy
Cysticercosis - parasitology
Drug Combinations
drug interactions
Drug resistance
Drug Synergism
Hypotheses
in vitro activity
Medical sciences
metacestodes ultrastructure
Mice
Mice, Inbred BALB C
Microscopy, Electron, Transmission
Parasites
Parasitic Sensitivity Tests
Pharmacology
Pharmacology. Drug treatments
Taenia - drug effects
Taenia - isolation & purification
Taenia - ultrastructure
Thiazoles - pharmacology
Title Efficacy of nitazoxanide, tizoxanide and tizoxanide/albendazole sulphoxide combination against Taenia crassiceps cysts
URI https://api.istex.fr/ark:/67375/HXZ-WXDZ2G8F-R/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/17114175
https://www.proquest.com/docview/217698350
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bj9JAFJ6Q3cSYGKPrZXGVTKLhBbpLy7RlHskKS8y6SwxEsi_N3Kp1yyVcDPCT_RWe6bS0JLhRXxp6m5Z-X8-cMz3nG4Q-uJxDRxTC-w3dmUUIZxaziW-5LBSNlpTUVkmC7I3XG5JPI3dUKv0qZC2tlvxcbA_WlfwPqrANcNVVsv-A7K5R2AC_AV9YAsKw_CuMO1r_Qc_XrrMxIMjfTtdsEhkh3WWUrZkkySjf2WUxVxCKb3VmoUlPX-vj4BYhTjaMYN9YBJ5jbcB0Nl5NzMHJBpsyW9TEZmHUnw74tABTNI4SbSetO_JdjdMCr93AfZ_F07GuebLaMTyWaeY8i2iRJw31ozhi0nwTWoEBumTzeLooNKG0SEgypL9iksWr2Y6et_CUtlY_ZsYrbsdpv5MNbPhZLnQWBpuCycJoXFrypV3vdIaTbLQkLQBruJZPjPbwuTL2nHgNoIyZECwz-C4tENvZs97OwV7FKG79YAKW8j4mqUneE---uQ26w-vrYNAZDfb3mlgL_DStpablDo4dMIraGl-N8nQkz5Rt7v5EJqVLmxdw4Qtz2T3n6VjbgXVWmPlkxgCnODSI_TleSvymwTP0NCUHbhv2PkclNTlBjz6nKR0nqNo34umbOh7ktYCLOq7ifi6rvnmBfmZsx9MQF9lexzm5McBVWL0oMB3nTMcFpuOU6dgwHedMxwnTX6JhtzO47FnprCGWIMRbgr2Rvu2oBmWO7xI7ZJT70hHCFYTpKTQF8wR1ZEsp0eLck4pyBW6r44eSuHBq8xU6mkwn6hRhxZuMebayQ0kJp7TFHUkbktlCOFTYjTJ6n8ERzIw4TGCSOpoBgBYY0MqomiC1O4TN73U6pe8GvdFd8HX08c65anWDL2VUASgfbKmyh3J-KDjdFLrTMjrLYA9SO7UIHNv3KARacLuvDRPy83zbJhBAvHnwvDP0OH8_36Kj5Xyl3oErvuSVhMO_AdDk6lA
link.rule.ids 315,783,787,27936,27937
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+nitazoxanide%2C+tizoxanide+and+tizoxanide%2Falbendazole+sulphoxide+combination+against+Taenia+crassiceps+cysts&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=Palomares-Alonso%2C+Francisca&rft.au=Piliado%2C+Juan+Carlos&rft.au=Palencia%2C+Guadalupe&rft.au=Ortiz-Plata%2C+Alma&rft.date=2007-02-01&rft.pub=Oxford+Publishing+Limited+%28England%29&rft.issn=0305-7453&rft.eissn=1460-2091&rft.volume=59&rft.issue=2&rft.spage=212&rft_id=info:doi/10.1093%2Fjac%2Fdkl463&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=1317810171
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7453&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7453&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7453&client=summon